Posted on

Dual Therapy for HIV Two-Stepping In

Posted on

Two-drug regimens may be as effective and safe as multi-drug therapies, according to investigators evaluating paired down treatment options for HIV.

“I don’t mean to say that everyone should be on dual therapy,” but it could be the beginning of a new era in HIV treatment, said Pedro Cahn, MD, from the Buenos Aires University Medical School in Argentina.

Previous attempts to treat people living with HIV with only two drugs were found to be ineffective at suppressing the HIV virus and led to drug resistance.

But results from a prespecified secondary analysis of data from the GEMINI studies (NCT02831673 and NCT02831764), presented here at the International AIDS Society (IAS) 2019 Conference on HIV Science, showed that the two-drug regimen of dolutegravir and lamivudine (Dovato, ViiV Healthcare) suppresses HIV in people new to treatment for 96 weeks, with zero drug-resistant mutations.

Also presented at the meeting were results from the TANGO study (NCT03446573), which demonstrated that the combination of dolutegravir and lamivudine is as effective, as durable, and as free of resistance at 48 weeks as traditional triple therapy in people who switch from three-drug regimens, and results from a phase 2b trial of 121 people that showed that islatravir, Merck’s investigational agent, plus doravirine is as safe and effective as a three-drug regimen at 48 weeks.

These findings add to the body of evidence established by the SWORD 1 and 2 trials, which showed that dolutegravir plus rilpivirine is effective in people switching from three-drug regimens.

Together, the findings provide an opportunity “to think about the position of dual therapy in international guidelines.”

GEMINI and TANGO

This time last year, Cahn was on another stage talking about similar data, At the time, the 1433 participants in GEMINI 1 and 2 had been on their new regimen for 48 weeks. Rates of viral loads below 50 copies/mL were comparable in patients treated with the two-drug and three-drug regimens in GEMINI 1 (90% vs 93%) and GEMINI 2 (93% vs 94%).

At 48 weeks, the rate of viral suppression (<50 copies/mL) was similar in the dolutegravir plus lamivudine group and the dolutegravir plus tenofovir disoproxil fumarate and emtracitabine (Truvada, Gilead Sciences) group (91.5% vs 93.3%).

But when Cahn presented those data last year, there were questions about the durability of the response and whether resistance could develop.

Durable Response

This year, Cahn was able to report that the response is durable and resistance did not develop. The combination of dolutegravir plus lamivudine “has been shown to be as effective as triple therapy,” he explained.

-GDMeds, an India Pharmacy Service company
 [Disclaimer]The Site is operated by GDMeds and all rights thereto are owned and reserved by GDMeds. The contents and works on these pages compiled by GDMeds are subject to copyright law. Copying, processing, distribution and any kind of use outside the limits of copyright law require the written consent of GDMeds In case the content is not created by GDMeds the copyrights of third parties are being observed. However, if a user becomes aware of a copyright infringement, GDMeds asks the user for notification. Upon notification of such violations, GDMeds will remove the content immediately.
[免责声明]本网站由印度极得美运营。印度极得美拥有和保留一切权利。印度极得美的网页内容及文档受版权法保护。复制、加工、传播及任何超出版权法限制的任何使用行为均必须得到印度极得美书面许可。如相关内容如非由印度极得美创作,需遵守第三方的版权,特别是标示为第三方内容的。如用户发现侵犯版权的行为,请通知极得美。一旦收到违反通知,极得美将立刻移除相关内容。
[отказ]Сайт управляется GDMeds, и все права на него принадлежат и зарезервированы GDMeds. Содержание и работы на этих страницах, составленные GDMeds, защищены законом об авторском праве. Копирование, обработка, распространение и любое использование вне пределов авторского права требуют письменного согласия GDMeds. Если контент не создан GDMeds, то соблюдаются авторские права третьих лиц. Однако, если пользователь узнает о нарушении авторских прав, GDMeds запрашивает у пользователя уведомление. После уведомления о таких нарушениях GDMeds немедленно удалит контент.